Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, enclosed herewith the link for the Transcript of the Q2 FY2024 Earnings Call conducted on October 18, 2023.
Syngene International Share Price Live blog for 20 Oct 2023
Syngene International stock price went down today, 20 Oct 2023, by -1.81 %. The stock closed at 727.35 per share. The stock is currently trading at 714.15 per share. Investors should monitor Syngene International stock price closely in the coming days and weeks to see how it reacts to the news. Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, enclosed herewith a copy of Newspaper publication dated October 19, 2023. Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), please find the link for the audio recording of the Q2 FY24 Earnings Call conducted on October 18, 2023 and uploaded on website of the Company on October 18, 2023.
Syngene International Results Earnings Call for Q2FY24
Conference Call with Syngene International Management and Analysts on Q2FY24 Performance and Outlook. Listen to the full earnings transcript.
Syngene MD and CEO Jonathan Hunt expects US Biotech segments recovery by Q4 after having cut company's FY24 guidance
Q2 results: Syngene International has cut its FY24 growth guidance to mid-teens on a constant currency basis compared to earlier guidance of high-teen growth due to US-based biotech segment showing signs of slowed growth. Jonathan Hunt MD and CEO of Syngene expects growth to rebound in Q4 Q2FY24 Quarterly & H1FY24 Bi-Annual Result Announced for Syngene International Ltd.
Pharmaceuticals company Syngene International announced Q2FY24 & H1FY24 results: Financial Results: - Revenue from operations for Q2FY24 increased by 18.5% to Rs 910 crore. - PAT (before exceptional items) for Q2FY24 increased by 20% to Rs 122 crore. - For H1FY24, revenue from operations increased by 22% to Rs 1,718 crore. - PAT (before exceptional items) for H1FY24 increased by 23% to Rs 215 crore. Business Updates: - Development and Manufacturing Services performed strongly during the quarter. - Syngene added a new non-GMP capability center to meet market demand for early-phase development and scale-up services. - In Manufacturing, good progress was made on the biologics partnership with Zoetis. - A state-of-the-art Quality Control laboratory was commissioned to support biologics operations. - The acquisition of a multi-modal facility from Stelis Biopharma Ltd is progressing. - Dedicated Centers and Discovery Services made steady contributions to growth. - The US-based biotech segment showed signs of slowed growth. Commenting on the quarter, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International, said, “I am pleased to report a strong set of results for the second quarter and first half of the financial year, particularly in our Development and Manufacturing Services. In Development Services, we also added a new non-GMP capability center to meet market demand for agile, cost-efficient, early-phase development and scale-up services. In Manufacturing, we made good progress on our long-term biologics partnership with Zoetis, as well as commissioning a state-of-the-art, digitally-enabled Quality Control laboratory to support our growing biologics operations. The acquisition of a multi-modal facility from Stelis Biopharma Ltd, announced last quarter, is progressing. Within research services, our Dedicated Centers made a steady contribution to growth and in Discovery Services, while global demand remained generally healthy, we saw the US-based biotech segment showing signs of slowed growth year-on-year as companies adjust to a new funding environment. Long-term sector fundamentals remain strong and we expect continued growth but at a lower level in the second half of the year, this short-term slowing in the US biotech segment is reflected in our latest outlook. Overall, we reported a strong first half to the year and I am pleased with the good progress made on our strategic priorities in both our research services and our development and manufacturing divisions.” Result PDF Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter and half year ended September 30, 2023. Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release dated October 17, 2023. Syngene International Ltd - 539268 - Board Meeting Outcome for Outcome Of The Board Meeting - October 17, 2023.
Outcome of the Board Meeting - October 17, 2023.